Adds 7-hydroxymitragynine and mitragynine pseudoindoxyl to Schedule I of the Controlled Substances Act, exempting kratom products that stay under set concentration limits, and lets federal authorities prosecute manufacturers and distributors of certain synthetic opioids as Schedule I drugs while barring penalties for personal possession.

• Adds 7-hydroxymitragynine and mitragynine pseudoindoxyl, including their salts, isomers, esters, and synthetic analogs, to Schedule I of the Controlled Substances Act.
• Exempts naturally occurring amounts in kratom products up to 1 milligram per gram for solid or powdered products, 1 milligram per milliliter for liquids, and 1 part per 100 parts mitragynine by mass.
• Denies the exemption to any of these compounds that are synthesized, concentrated, isolated, or otherwise manufactured.
• Treats covered emerging synthetic opioids as Schedule I substances for knowing manufacture, distribution, and possession with intent to distribute in commercial distribution.
• Bars investigation, arrest, charges, or civil penalties for simple possession or personal use of those opioids, and excludes FDA-approved drugs, research and forensic materials, and botanical constituents unless isolated or added to products.

• Judiciary Committee (Senate)

Crime and Law Enforcement